Head-To-Head Review: Sientra (SIEN) vs. Antares Pharma (ATRS)

Sientra (NASDAQ: SIEN) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Volatility & Risk

Sientra has a beta of -1.44, suggesting that its share price is 244% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Institutional and Insider Ownership

77.6% of Sientra shares are held by institutional investors. Comparatively, 36.8% of Antares Pharma shares are held by institutional investors. 28.1% of Sientra shares are held by insiders. Comparatively, 11.6% of Antares Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sientra and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sientra -173.83% -52.30% -37.51%
Antares Pharma -34.27% -41.37% -25.74%

Valuation & Earnings

This table compares Sientra and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sientra $28.68 million 9.79 -$35.42 million ($2.66) -5.47
Antares Pharma $53.10 million 5.66 -$15.90 million ($0.12) -16.00

Antares Pharma has higher revenue and earnings than Sientra. Antares Pharma is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sientra and Antares Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sientra 0 1 4 0 2.80
Antares Pharma 0 0 3 1 3.25

Sientra presently has a consensus target price of $13.75, suggesting a potential downside of 5.50%. Antares Pharma has a consensus target price of $3.95, suggesting a potential upside of 105.73%. Given Antares Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Antares Pharma is more favorable than Sientra.

Summary

Antares Pharma beats Sientra on 10 of the 14 factors compared between the two stocks.

Sientra Company Profile

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

What are top analysts saying about Sientra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sientra Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit